Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety

International Journal of Women's Health
Henri Leminen, Ritva Hurskainen


Tranexamic acid has proven to be an effective treatment for heavy menstrual bleeding (HMB). It reduces menstrual blood loss (MBL) by 26%-60% and is significantly more effective than placebo, nonsteroidal anti-inflammatory drugs, oral cyclical luteal phase progestins, or oral etamsylate, while the levonorgestrel-releasing intrauterine system reduces MBL more than tranexamic acid. Other treatments used for HMB are oral contraceptives, danazol, and surgical interventions (endometrial ablation and hysterectomy). Medical therapy is usually considered a first-line treatment for idiopathic HMB. Tranexamic acid significantly improves the quality of life of women treated for HMB. The recommended oral dosage is 3.9-4 g/day for 4-5 days starting from the first day of the menstrual cycle. Adverse effects are few and mainly mild. No evidence exists of an increase in the incidence of thrombotic events associated with its use. An active thromboembolic disease is a contraindication. In the US, a history of thrombosis or thromboembolism, or an intrinsic risk for thrombosis or thromboembolism are considered contraindications as well. This review focuses on the efficacy and safety of tranexamic acid in the treatment of idiopathic HMB. We searched...Continue Reading


Aug 1, 1990·British Journal of Obstetrics and Gynaecology·J M HighamR W Shaw
Apr 1, 1987·European Journal of Obstetrics, Gynecology, and Reproductive Biology·C J DockerayJ Bonnar
Jan 1, 1988·Acta Obstetricia Et Gynecologica Scandinavica·B AnderschG Rybo
Mar 21, 1987·British Medical Journal·M Rees
Aug 23, 1974·European Journal of Clinical Pharmacology·O ErikssonM Schannong
Oct 24, 1970·British Medical Journal·S T CallenderE Cope
Jan 1, 1966·Acta Obstetricia Et Gynecologica Scandinavica·L HallbergG Rybo
Apr 1, 1981·British Journal of Obstetrics and Gynaecology·S K SmithD T Baird
Jan 1, 1981·European Journal of Clinical Pharmacology·A PilbrantJ Vessman
May 1, 1995·British Journal of Obstetrics and Gynaecology·J T PrestonS K Smith
Feb 23, 1999·Human Reproduction Update·P A RogersN Taylor
Oct 18, 2000·The Cochrane Database of Systematic Reviews·A LethabyI Cooke
Jul 5, 2001·Fertility and Sterility·K M WyattP M O'Brien
Jan 15, 2002·European Journal of Obstetrics, Gynecology, and Reproductive Biology·U H Winkler
Jul 30, 2002·European Journal of Haematology·Minakshi TapariaMichael F Leahy
Jun 27, 2003·Drugs·Keri Wellington, Antona J Wagstaff
Jan 1, 1964·Scandinavian Journal of Clinical and Laboratory Investigation·L HALLBERG, L NILSSON
Oct 31, 2006·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·A KriplaniS Diwakar
May 30, 2007·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Zhimei LiuRobert W Dubois
Sep 23, 2010·Obstetrics and Gynecology·Andrea S LukesGary A Shangold
Oct 15, 2010·Current Medical Research and Opinion·Andrea S LukesDonald L Patrick
Jul 23, 2011·American Journal of Obstetrics and Gynecology·Ellen W FreemanTammie L Adomako

❮ Previous
Next ❯


Jan 7, 2015·Thrombosis Research·Lilian TengbornErik Berntorp
Mar 11, 2015·The Australasian Journal of Dermatology·Michelle Rodrigues, Amit G Pandya
Dec 4, 2014·Best Practice & Research. Clinical Obstetrics & Gynaecology·Mourad W SeifMahshid Nickkho-Amiry
May 29, 2016·The American Journal of Emergency Medicine·Ramazan Güven
Jul 24, 2020·The Cochrane Database of Systematic Reviews·Magdalena Bofill RodriguezJames Mn Duffy
May 12, 2016·Experimental and Therapeutic Medicine·Igor GovorovMiriam Mints
May 8, 2015·Anesthesiology·Andreas KosterJerrold H Levy
Mar 7, 2019·Biochemical Society Transactions·Guojie WuRuby H P Law
Sep 27, 2018·Case Reports in Dentistry·Rocco FrancoPatrizio Bollero
May 6, 2017·Anesthesiology·Irene LeckerBeverley A Orser
Aug 28, 2020·Journal of Complementary & Integrative Medicine·Rayeesa Banu R UmaramiMohd Aqil Quadri

❮ Previous
Next ❯

Methods Mentioned


Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.